Lornoxicam Tablets

Pharmacological action: Lornoxicam is a non-steroidal anti-inflammatory analgesic and a thiazide derivative. It inhibits the synthesis of prostaglandins by inhibiting the activity of cyclooxygenase (COX), and has strong analgesic and anti-inflammatory effects. Toxicological studies: In vivo safety studies in animals have shown that the toxicity characteristics of this product are consistent with its inhibitory effects on cyclooxygenase, and the digestive tract and kidneys are the most sensitive organs to toxicity. Repeated dose toxicity: SD rats were given 0, 0.06, 0.16, and 0.40 mg/kg/day by oral gavage for 12 consecutive months. The main toxicities associated with the administration included death, slowed weight gain, anemia caused by blood loss, renal damage, renal papillary necrosis, and gastrointestinal mucosal damage; renal lesions were not completely recovered during the recovery observation period.

Lornoxicam

This product is a film-coated tablet, which is yellow after removing the coating

It can be used for acute pain after surgery, moderate to severe pain caused by trauma, acute sciatica and low back pain, and advanced cancer pain. It can also be used to treat chronic low back pain, osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

For the treatment of arthritis or chronic pain, take 8 mg/time (1 tablet) orally, twice a day. For acute pain, take a single or multiple doses orally depending on the severity of the pain, with the total daily dose not exceeding 32 mg (4 tablets).

The most common adverse reactions are gastrointestinal reactions, including: nausea, vomiting, stomach burning, indigestion, and some individuals experience gastric ulcers, gastric perforation, and gastrointestinal bleeding.

It is contraindicated for patients with peptic ulcer and hemorrhagic diseases, severe liver and kidney dysfunction, renal failure, and those who are allergic to the ingredients of this product.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: This experiment has not been conducted and there is no reliable reference. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

Pharmacokinetic studies have shown that when ranitidine or antacids containing aluminum, potassium, calcium or bismuth are taken simultaneously with lornoxicam, there is no significant change in the pharmacokinetics of lornoxicam; however, when cimetidine is taken simultaneously with lornoxicam, the former inhibits the elimination of lornoxicam, resulting in a significant increase in the steady-state Cmax (28%) and AUC (9%) values, while the apparent plasma clearance rate decreases (12%). Similar to several other NSAIDs, lornoxicam can significantly reduce (30%) the plasma concentration of warfarin and enhance its anticoagulant effect. Lornoxicam causes a slight decrease (15%) in the steady-state plasma digoxin clearance of healthy volunteers, without significant effects on other pharmacokinetic parameters. Conversely, digoxin (0.25 mg/kg) reduces the clearance of lornoxicam from plasma digoxin.

Keep in a light-proof and airtight container. Valid for 18 months

8mg

Tentative 18 months

Heilongjiang Wusulijiang Pharmaceutical Co., Ltd. Harbin Branch

• Founded in:

  2001-07-23

• Address:

  No. 39, Bohai Road, Central Area, Haping Road, Harbin Development Zone

• Tax NO.:

  91230199731340543C

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view